{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:03:42Z","timestamp":1783569822753,"version":"3.55.0"},"reference-count":28,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Belantamab mafodotin is the first\u2010in\u2010class antibody\u2010drug conjugates targeting B\u2010cell maturation antigen to have demonstrated effectiveness in triple\u2010class refractory multiple myeloma (TCR\u2010MM) patients. We performed a retrospective study including 78 TCR patients, with at least four prior lines of therapy (LOTs), who received belantamab mafodotin within named patient program and expanded access program in Italy between 2020 and 2022. Median age was 65 years (range 42\u201386 years), ECOG performance status was \u22651 in 45% of patients. Overall, a clinical benefit was obtained in 36 out of 74 evaluable patients (49%), with 43%, 28%, and 13.5% achieving at least partial response, very good partial response, and complete response, respectively. After a median follow\u2010up of 12 months (range 6\u201321 months), median duration of response, progression\u2010free survival (PFS), and overall survival (OS) were 14, 5.5, and 12 months, respectively. Age &gt;70 years, good performance status and response were associated with longer PFS and OS. Keratopathy occurred in 58% of patients (G3 2.5%), corneal symptoms in 32% (G3 1.2%) and a reduction in visual acuity in 14%. Grade 3 thrombocytopenia occurred in 9% of patients. Only 3% of patients discontinued belantamab mafodotin because of side effects. This real\u2010life study demonstrated significant and durable responses of belantamab in TCR\u2010MM patients with four prior LOTs, otherwise ineligible for novel immunotherapies.<\/jats:p>","DOI":"10.1002\/jha2.907","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T05:39:26Z","timestamp":1714541966000},"page":"485-493","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Belantamab mafodotin in triple\u2010refractory multiple myeloma patients: A retro\u2010prospective observational study in Italy"],"prefix":"10.1002","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4187-8912","authenticated-orcid":false,"given":"Francesca","family":"Fazio","sequence":"first","affiliation":[{"name":"Hematology Unit, Department of Translational and Precision Medicine Azienda Ospedaliera Policlinico Umberto I Sapienza University of Rome  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Petrucci","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Translational and Precision Medicine Azienda Ospedaliera Policlinico Umberto I Sapienza University of Rome  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Corvatta","sequence":"additional","affiliation":[{"name":"Unit\u00e0 Operativa Complessa di Medicina Ospedale Profili  Fabriano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Piciocchi","sequence":"additional","affiliation":[{"name":"GIMEMA Foundation  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta Della","family":"Pepa","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Clinical Medicine and Surgery University of Naples \u201cFederico II\u201d  Naples Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Tacchetti","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero\u2010Universitaria di Bologna\u2010Istituto di Ematologia \u201cSer\u00e0gnoli\u201d  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Musso","sequence":"additional","affiliation":[{"name":"Oncoematology\u00a0and BMT Unit, Oncology Department Ospedale La maddalena Palermo  Palermo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8799-5324","authenticated-orcid":false,"given":"Renato","family":"Zambello","sequence":"additional","affiliation":[{"name":"Hematology Unit Department of Medicine University of Padova  Padua Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Belotti","sequence":"additional","affiliation":[{"name":"Department of Hematology ASST Spedali Civili di Brescia  Brescia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bringhen","sequence":"additional","affiliation":[{"name":"SSD Clinical Trial in Oncoematologia e Mieloma Multiplo Department of Oncology Azienda Ospedaliero\u2010Universitaria Citt\u00e0 della Salute e della Scienza di Torino  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Antonioli","sequence":"additional","affiliation":[{"name":"Haematology Unit Careggi University Hospital  Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Conticello","sequence":"additional","affiliation":[{"name":"Division of Haematology and BMT A.O.U. \u2018Policlinico\u2010San Marco\u2019  Catania Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola Di","family":"Renzo","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplant Unit \u201cVito Fazzi\u201d Hospital  Lecce Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5178-5827","authenticated-orcid":false,"given":"Valerio","family":"De Stefano","sequence":"additional","affiliation":[{"name":"Section of Hematology Department of Radiological and Hematological Sciences Catholic University Fondazione Policlinico A Gemelli IRCCS  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pellegrino","family":"Musto","sequence":"additional","affiliation":[{"name":"Department of Precision and Regenerative Medicine and Ionian Area \u201cAldo Moro\u201d University School of Medicine, and Unit of Hematology and Stem Cell Transplantation AOUC Policlinico  Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3616-5838","authenticated-orcid":false,"given":"Barbara","family":"Gamberi","sequence":"additional","affiliation":[{"name":"Hematology Unit Azienda USL\u2010 IRCCS di Reggio Emilia  Reggio Emilia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Derudas","sequence":"additional","affiliation":[{"name":"SC di Ematologia e CTMO \u2010 Oncologico Oncologico di Riferimento Regionale \u201cA. Businco\u201d \u2010 ARNAS \u201cG. Brotzu\u201d  Cagliari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Boccadoro","sequence":"additional","affiliation":[{"name":"European Myeloma Network  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2749-7347","authenticated-orcid":false,"given":"Massimo","family":"Offidani","sequence":"additional","affiliation":[{"name":"Department of Hematology Azienda Ospedaliero Universitaria delle Marche  Ancona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Mor\u00e8","sequence":"additional","affiliation":[{"name":"Department of Hematology Azienda Ospedaliero Universitaria delle Marche  Ancona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,4,30]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01531-2"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34987"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00592-3"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15112964"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411829"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.8060"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18298"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e20046"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18479"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1026251"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000936260.48784.ae"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281772"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-171077"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-164929"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18479"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010166399"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010158538"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010156035"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(22)00606-1"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx096"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010021\u201000494\u20104"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e20021"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01365"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.03.012"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2023.14.6.4"},{"key":"e_1_2_13_29_1","unstructured":"RousselM TexierN GermainR SapraS PakaP KerboucheN.Effectiveness and safety of belantamab mafodotin in patients with relapsed or refractory multiple myeloma in real\u2010life setting: the ALFA study. 64th ASH Annual Meeting and Exposition.2022; (Abs 1856)."}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.907","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T15:41:04Z","timestamp":1724168464000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,30]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1002\/jha2.907"],"URL":"https:\/\/doi.org\/10.1002\/jha2.907","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,30]]},"assertion":[{"value":"2024-01-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}